25 insiders reported 61 Form 4 transactions for Lyell Immunopharma, Inc. (LYEL) over the past 18 months (most recent 2026-07-01). Recent activity: Innovative Cellular Therapeutics Holdings Ltd (Insider) Sell 76,000 shares, Innovative Cellular Therapeutics Holdings Ltd (Insider) Sell 66,500 shares, Shook David (Chief Medical Officer) Sell 1,977 shares, ARCH Venture Fund IX, L.P. (Insider) Buy 488,090 shares, CRANDELL KEITH (Insider) Buy 488,090 shares. Source: SEC Form 4.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-01 | Innovative Cellular Therapeutics Holdings Ltd | Insider | Sell | 76,000 | $0 |
| 2026-06-18 | Innovative Cellular Therapeutics Holdings Ltd | Insider | Sell | 66,500 | $0 |
| 2026-06-11 | Shook David | Chief Medical Officer | Sell | 1,977 | $24,989 |
| 2026-03-09 | ARCH Venture Fund IX, L.P. | Insider | Buy | 488,090 | $12.5M |
| 2026-03-09 | CRANDELL KEITH | Insider | Buy | 488,090 | $12.5M |
| 2026-03-09 | NELSEN ROBERT | Insider | Buy | 488,090 | $12.5M |
| 2026-03-09 | BYBEE CLINTON | Insider | Buy | 488,090 | $12.5M |
| 2026-03-09 | BERNS PAUL L | Insider | Buy | 488,090 | $12.5M |
| 2026-03-09 | Burow Kristina | Insider | Buy | 488,090 | $12.5M |
| 2026-03-09 | ARCH Venture Fund XIII, L.P. | Insider | Buy | 488,090 | $12.5M |
| 2026-03-09 | ARCH Venture Partners XIII, LLC | Insider | Buy | 488,090 | $12.5M |
| 2026-03-09 | ARCH Venture Partners XIII, L.P. | Insider | Buy | 488,090 | $12.5M |
| 2026-03-09 | GILLIS STEVEN | Insider | Buy | 488,090 | $12.5M |
| 2026-03-09 | ARCH Venture Fund IX Overage, L.P. | Insider | Buy | 488,090 | $12.5M |
| 2026-03-09 | ARCH Venture Partners IX Overage, L.P. | Insider | Buy | 488,090 | $12.5M |
| 2026-03-09 | ARCH Venture Partners IX, L.P. | Insider | Buy | 488,090 | $12.5M |
| 2026-03-09 | ARCH Venture Partners IX, LLC | Insider | Buy | 488,090 | $12.5M |
| 2026-02-12 | Hill Stephen J. | Chief Operating Officer | Sell | 1,236 | $28,910 |
| 2026-02-12 | Lee Gary K. | Chief Scientific Officer | Sell | 1,671 | $39,085 |
| 2026-02-12 | Seely Lynn | President and CEO | Sell | 7,455 | $174,372 |
| 2026-02-11 | Lee Gary K. | Chief Scientific Officer | Buy | 4,000 | $0 |
| 2026-02-11 | Lee Gary K. | Chief Scientific Officer | Sell | 147 | $3,399 |
| 2026-02-11 | Hill Stephen J. | Chief Operating Officer | Buy | 4,000 | $0 |
| 2026-02-11 | Hill Stephen J. | Chief Operating Officer | Sell | 109 | $2,520 |
| 2026-02-11 | Seely Lynn | President and CEO | Buy | 20,000 | $0 |
Source: SEC Form 4 filings · as of 2026-07-01